For the year ending 2025-12-31, SLNO had -$17,822K decrease in cash & cash equivalents over the period. $46,725K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 20,890 |
| Depreciation and amortization | 2,017 |
| Accretion of premium/discount on marketable securities | 3,517 |
| Non-cash lease expense | 607 |
| Amortization of debt issuance costs | 35 |
| Stock-based compensation expense | 45,846 |
| Change in fair value of stock warrants | 0 |
| Change in fair value of contingent consideration | 5,536 |
| Other non-cash reconciling items | -17 |
| Accounts receivable | 28,208 |
| Inventory | 14,031 |
| Prepaid expenses, other current assets and other assets | 4,738 |
| Accounts payable | 3,612 |
| Accrued compensation | 4,901 |
| Operating lease liabilities | -308 |
| Other liabilities | 14,139 |
| Net cash provided by (used in) operating activities | 46,798 |
| Purchases of property and equipment | 73 |
| Purchases of marketable securities | 455,776 |
| Maturities of marketable securities | 254,068 |
| Net cash used in investing activities | -201,781 |
| Proceeds from issuance of debt, net of issuance costs | 0 |
| Payment of debt issuance costs | 62 |
| Proceeds from the sale of common stock, net of issuance costs | 215,721 |
| Proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs | 0 |
| Payment for repurchase of common stock | 100,146 |
| Proceeds from exercise of common stock and pre-funded stock warrants | 5,187 |
| Proceeds from exercise of stock options | 17,202 |
| Tax withholding payments for net share-settled equity awards | 741 |
| Net cash provided by financing activities | 137,161 |
| Net increase (decrease) in cash and cash equivalents | -17,822 |
| Cash and cash equivalents, beginning of period | 87,928 |
| Cash and cash equivalents, end of period | 70,106 |
SOLENO THERAPEUTICS INC (SLNO)
SOLENO THERAPEUTICS INC (SLNO)